insurance company board independent director: protect promises that mature years later

An insurance company board independent director is not expected to reproduce the appointed actuary’s models, but cannot treat the actuarial certificate as the end of inquiry. Premium growth changes exposure before claims experience fully emerges. Directors should understand which assumptions drive reserves, how actual mortality, morbidity, lapses, expenses or claim severity compare with expectation, and where management has changed methodology or judgement. A movement bridge by product and cohort is more informative than one solvency number because it shows whether adverse experience is isolated, persistent or being offset by a favourable assumption elsewhere.

Model governance should preserve challenge around data, methodology and management overlay. The board needs to know whether policy administration data reconciles to the actuarial dataset, how experience studies are selected, what sensitivity surrounds the largest assumptions and who validates changes independently of the business that benefits from them. For long-duration products, small shifts in lapse, expense or discount assumptions can compound across years. Current IRDAI reserving and solvency requirements must be applied by qualified actuarial and legal professionals; the director’s contribution is to connect those conclusions with strategy, capital and policyholder consequences.

A product can meet an approval process and still create poor value when exclusions, surrender terms, waiting periods or illustrations are not understood by the customer it reaches. The board should review target market, benefit clarity, expected claims, persistency and complaint behaviour alongside margin. Distribution evidence should distinguish tied agents, brokers, bancassurance, digital partners and direct channels because training, incentives and control differ. High first-year sales with weak renewal, early surrender or repeated cancellation may reveal that the promise made at sale is not the promise the policyholder later recognises.

Commission and sales contests deserve attention at the level where behaviour changes. Ask whether quality measures can reverse reward, whether intermediaries with repeated complaints remain active, and whether vulnerable or low-literacy customers receive suitable explanation. Recorded consent or a long disclosure does not by itself prove comprehension. Product, distribution, compliance and grievance teams should share one account of recurring problems, including refunds and corrective communication. The board need not approve individual sales; it should ensure that commercial design, intermediary oversight and consequence management support fair treatment under the applicable IRDAI policyholder-protection framework.

Headline settlement ratios can conceal delay, disputed amounts and differences across products or channels. Directors should see claim ageing, repudiation reasons, partial settlements, litigation, reopened grievances and vulnerable-claimant outcomes. A death, health or catastrophe claim carries urgency that an annual average cannot express. Sampling files by reason and channel can reveal documentation demands, investigation practices or provider disputes that systematically burden certain customers. Where automation is used, the board should know which decisions remain human, how exceptions are escalated and whether the model disadvantages cases outside its normal pattern.

Outsourced administrators, surveyors, hospitals and investigators remain part of the insurer’s delivered service. Contract service levels should be compared with claimant experience, leakage controls and complaint evidence. Fraud prevention is legitimate, but an aggressive fraud target can delay genuine payment or encourage broad repudiation rules. The committee should examine incentives, independent review of contested decisions and remediation when a systemic error is found. Applicable claims, grievance and ombudsman requirements should be verified in their current form. This page offers governance education, not legal or actuarial advice for a particular insurer.

Investment return cannot be reviewed apart from duration, liquidity and credit quality of policy liabilities. A portfolio may meet allocation limits while still carrying concentration in one group, sector or market assumption. Directors should understand cash-flow matching, realised and unrealised losses, collateral, related exposure and the ability to fund claims during market stress without forced sale. Product guarantees and participating-policy expectations can constrain choices differently. The investment committee manages within mandate; the board tests whether asset strategy, solvency appetite and policyholder obligations remain aligned under plausible adverse experience.

Reinsurance reduces volatility only to the extent that coverage responds and the counterparty pays. Examine exclusions, attachment, reinstatement, concentration, disputes, collateral and collectability rather than treating ceded premium as completed transfer. Catastrophe accumulation may span regions or business lines that separate teams model independently. A severe event can also disrupt claims operations and investment markets together. The board should understand which residual loss remains, whether recoveries arrive after claims must be paid, and how a reinsurer downgrade or disputed wording affects capital. Specialists price and negotiate treaties; directors govern the reliance placed on them.

Policy administration, premium collection, hospital authorisation, claims payment and regulatory reporting may depend on different platforms and providers. Recovery evidence should follow a policyholder outcome from request to completed, reconciled transaction. Restoring an application is insufficient if documents, beneficiary data or payment instructions are incomplete. Directors should ask how identity and privileged access are controlled, how cyber incidents reach affected customers and whether manual workarounds create fresh privacy or fraud exposure. IRDAI information and cyber-security guidance should be mapped to the insurer’s service architecture and tested rather than answered with certification alone.

Before joining, a candidate should review solvency movement, reserving themes, persistency, claims disputes, distribution concentration, reinsurance collectability, investments, technology incidents and regulator correspondence. Meet the appointed actuary, risk, compliance, internal audit and claims leadership to understand whether uncomfortable evidence reaches the board promptly. Confirm Section 149(6) independence, insurer-specific fit-and-proper conditions, committee expectations, D&O wording and capacity for urgent meetings. A strong profile explains how the candidate has protected long-term customer promises under uncertainty, while being candid about where actuarial, clinical or legal expertise must remain with qualified professionals.